Hereditäre Disposition für Krebserkrankungen – Familiäres Mamma- und Ovarialkarzinom

K. Rhiem; R. K. Schmutzler

doi:10.1055/s-0032-1319595

Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents

Senologie - Zeitschrift für Mammadiagnostik und -therapie 2013; 10(2): 79-82
DOI: 10.1055/s-0032-1319595

Aktuell diskutiert

Georg Thieme Verlag KG Stuttgart · New York

Hereditäre Disposition für Krebserkrankungen – Familiäres Mamma- und Ovarialkarzinom

K. Rhiem

,

R. K. Schmutzler

Abstract

Full Text

References

Literatur
1 Meindl A, Ditsch N, Kast K et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dt Arzteblatt Intl 2011; 108: 323-330
2 Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Gen 2010; 42: 410-414
3 Rhiem K, Flucke U, Schmutzler RK. BRCA1-associated breast carcinomas frequently present with benign sonographic features. AJR 2006; 186: E11-12
4 Bosse K, Rhiem K, Wappenschmidt B et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gyn Oncol 2006; 103: 1077-1082
5 Graeser MK, Engel C, Rhiem K et al. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol 2009; 27: 5887-5892
6 Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Canc Res 2012; 14: R156
7 Rhiem K, Wappenschmidt B, Bosse K et al. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. Clin Oncol 2009; 21: 448-450
8 Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244
9 Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251
10 Ozretic L, Rhiem K, Huss S et al. High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive for BRCA1- and BRCA2-Deficient Breast Cancer. J Clin Oncol 2011; 29: 4586-4588